Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma

Toxicology

Volumn 256, Issue 1-2, 2009, Pages 135-140

  Wang, Jun ^a   Liu, Wei ^a   Zhao, Qing ^a   Qi, Qi ^a   Lu, Na ^a   Yang, Yong ^a   Nei, Fei Fei ^a   Rong, Jing Jing ^a   You, Qi Dong ^a   Guo, Qing Long ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; DPD OPRT; Gambogic acid; Metabolic enzymes; Synergism; TS

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GAMBOGIC ACID; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANNEXIN A5; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; XANTHONES;

EID: 58149218002     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.11.014     Document Type: Article

References (27)

1. Ajani J.A. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 12 (1998) 44-47
2. Auterhoff H., Frauendorf H., Liesenklas W., and Schwandt C. The chief constituents of gamboge resins. 1. Chemistry of gamboge. Arch. Pharm. 295 (1962) 833-846
3. Boyer J., McLean E.G., Aroori S., Wilson P., McCulla A., Carey P.D., Longley D.B., and Johnston P.G. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res. 10 (2004) 2158-2167
4. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006) 621-681
5. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
6. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 86 (1994) 1517-1524
7. Fujii R., Seshimo A., and Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int. J. Clin. Oncol./Jpn. Soc. Clin. Oncol. 8 (2003) 72-78
8. Glimelius B., Hoffman K., Haglund U., Nyren O., and Sjoden P.O. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann. Oncol. 5 (1994) 189-190
9. Glimelius B., Ekstrom K., Hoffman K., Graf W., Sjoden P.O., Haglund U., Svensson C., Enander L.K., Linne T., Sellstrom H., and Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8 (1997) 163-168
10. Guo Q.L., Lin S.S., You Q.D., Gu H.Y., Yu J., Zhao L., Qi Q., Liang F., Tan Z., and Wang X. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 78 (2006) 1238-1245
11. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., and Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55 (1995) 1407-1412
12. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40 (2004) 827-836
13. Kornmann M., Schwabe W., Sander S., Kron M., Strater J., Polat S., Kettner E., Weiser H.F., Baumann W., Schramm H., Hausler P., Ott K., Behnke D., Staib L., Beger H.G., and Link K.H. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin. Cancer Res. 9 (2003) 4116-4124
14. Lim Y.J., Rhee J.C., Bae Y.M., and Chun W.J. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J. Gastroenterol. 13 (2007) 1947-1952
15. Liu W., Guo Q.L., You Q.D., Zhao L., Gu H.Y., and Yuan S.T. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J. Gastroenterol. 11 (2005) 3655-3659
16. Murad A.M., Santiago F.F., Petroianu A., Rocha P.R., Rodrigues M.A., and Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
17. Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Stem Cells (Dayton, Ohio) 18 (2000) 166-175
18. Peters G.J., and van Groeningen C.J. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2 (1991) 469-480
19. Shabbits J.A., Hu Y., and Mayer L.D. Tumor chemosensitization strategies based on apoptosis manipulations. Mol. Cancer Ther. 2 (2003) 805-813
20. Wada Y., Yoshida K., Suzuki T., Mizuiri H., Konishi K., Ukon K., Tanabe K., Sakata Y., and Fukushima M. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int. J. Cancer 119 (2006) 783-791
21. Wohrer S.S., Raderer M., and Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. 15 (2004) 1585-1595
22. Yang Y., Yang L., You Q.D., Nie F.F., Gu H.Y., Zhao L., Wang X.T., and Guo Q.L. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 256 (2007) 259-266
23. Yim E.K., Lee K.H., Bae J.S., Namkoong S.E., Um S.J., and Park J.S. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol. 23 (2004) 769-776
24. Yim E.K., Lee S.B., Lee K.H., Kim C.J., and Park J.S. Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells. Int. J. Gynecol. Cancer 16 (2006) 1321-1329
25. Yu J., Guo Q.L., You Q.D., Lin S.S., Li Z., Gu H.Y., Zhang H.W., Tan Z., and Wang X. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemother. Pharmacol. 58 (2006) 434-443
26. Yu J., Guo Q.L., You Q.D., Zhao L., Gu H.Y., Yang Y., Zhang H.W., Tan Z., and Wang X. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28 (2007) 632-638
27. Zhao L., Guo Q.L., You Q.D., Wu Z.Q., and Gu H.Y. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol. Pharm. Bull. 27 (2004) 998-1003